(Q42999434)

12 November 2017

title

Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C. (English)

1 reference

12 November 2017

Guilera M

1

1 reference

12 November 2017

Forns X

2

1 reference

12 November 2017

Torras X

3

1 reference

12 November 2017

Enríquez J

4

1 reference

12 November 2017

Coll S

5

1 reference

12 November 2017

Solà R

6

1 reference

12 November 2017

Morillas R

7

1 reference

12 November 2017

Planas R

8

1 reference

12 November 2017

Ampurdanès S

9

1 reference

12 November 2017

Soler M

10

1 reference

12 November 2017

Costa J

11

1 reference

12 November 2017

Sáiz JC

12

1 reference

12 November 2017

Sánchez-Tapias JM

13

1 reference

12 November 2017

Rodés J

14

1 reference

12 November 2017

publication date

1 July 2000

1 reference

12 November 2017

published in

Journal of Hepatology

1 reference

12 November 2017

volume

33

1 reference

12 November 2017

issue

1

1 reference

12 November 2017

page(s)

135-141

1 reference

Therapy of hepatitis C: overview

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Hepatitis C virus infection: virus/host interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Effects of prednisolone pretreatment in interferon alfa therapy for patients with chronic non-A, non-B (C) hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Comparative study of a modified competitive RT-PCR and Amplicor HCV monitor assays for quantitation of hepatitis C virus RNA in serum

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Therapy of hepatitis C: other options

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Loss of serum HCV RNA at week 4 of interferon‐α therapy is associated with more favorable long‐term response in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Should patients with early loss of serum HCV-RNA during alpha interferon therapy for chronic hepatitis C be treated for 6 or 12 months?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

Factors predictive of a beneficial response to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980170-1

7 January 2021

10.1016/S0168-8278(00)80170-1

Identifiers

DOI

1 reference

12 November 2017

1 reference